Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Explore this paper's citation graph
Summary
Nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors, and the tumor mutational burden was predictive of the pathological response to PD‐1 blockade.
- Type
- article
- Published
- 2018-04-16
- Cited by
- 1,809
- References
- 34
- Access
- Open access
- OpenAlex
- https://openalex.org/W2798160602
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4891722
Keywords
Blockade, Medicine, Lung cancer, Neoadjuvant therapy, Oncology
References
- Pembrolizumab for the treatment of non-small-cell lung cancer.
- Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy
- Palindromic Nucleotide Analysis in Human T Cell Receptor Rearrangements
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
- Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
- Pathologic response after neoadjuvant chemotherapy in resectable non-small cell lung cancers: proposal for the use of “major pathologic response” as a surrogate endpoint
- Personalized genomic analyses for cancer mutation discovery and interpretation
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
- Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Comprehensive genomic characterization of squamous cell lung cancers
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
- Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition
Cited by
- Neoadjuvant PD-1 blockade in NSCLC
- Early Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
- Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
- Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art
- Stereotactic body radiotherapy for early-stage non-small cell lung cancer has low post-treatment mortality.
- Current and future developments of immunotherapy in lung cancer
- Myeloid Regulatory Cells: New and Exciting Players in the Immunology of Lung Cancer.
- The Immune Landscape of Non‐Small‐Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures
- PACIFIC: Time for a surgical IIIA uprising
- A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer
- New windows open for immunotherapy in lung cancer
- The Mutation-Associated Neoantigen Functional Expansion of Specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity
- Immune Checkpoint Blockade across the Cancer Care Continuum.
- Real-World Pseudoprogression: an Uncommon Phenomenon.
- Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
- Does oncology research need to slow down a little bit?
- Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
- Well‐controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report
- Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
Related papers
- Effect of Selective Blockade of α2C-Adrenoceptors on Cardiac Activity in Growing Rats
- [Gow-Gates block for beginners].
- Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
- Blockade and Geopolitics
- Through the Blockade: The Profitability and Extent of Cotton Smuggling, 1861–1865
- Blockade of specific antibody‐forming cells in vivo by dextrans and levans
- A Forgotten Front? The Mediterranean Blockade in the First World War
- Relationship between the potassium currents block and the occurrence of early after depolarizations in the setting of sodium current blockade
- Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.